Background Clinical benefit from programmed cell death 1 receptor (PD-1) inhibitors relies on reinvigoration of endogenous antitumor immunity. Nonetheless. robust immunological markers. based on circulating immune cell subsets associated with therapeutic efficacy are yet to be validated. https://www.jmannino.com/